| batefenterol (GSK961081) / GSK |
NCT00887406: Study of GSK961081 in Healthy Volunteer Subjects |
|
|
| Completed | 1 | 46 | Europe | GSK961081 15mcg SD, Placebo, GSK961081 200mcg SD, GSK961081 50mcg SD, GSK961081 300mcg SD, GSK961081 100mcg SD, GSK961081 3mcg SD, Placebo SD, GSK961081 100mcg RD, GSK961081 300mcg RD, Placebo RD | Theravance Biopharma, GlaxoSmithKline | Pulmonary Disease, Chronic Obstructive | 10/06 | 10/06 | | |
NCT00550225: Succinate Salt Version of GSK961081 for Healthy Volunteers |
|
|
| Completed | 1 | 18 | Europe | GSK961081, GSK961081 matching placebo | Theravance Biopharma, GlaxoSmithKline | Pulmonary Disease, Chronic Obstructive | 01/08 | 01/08 | | |
NCT00687700: A Study to Investigate the Pharmacology of a Dual Pharmacophore in Healthy Volunteers |
|
|
| Completed | 1 | 23 | Europe | GSK961081, GSK961081 matching placebo, Propranolol, Propranolol matching placebo | Theravance Biopharma, GlaxoSmithKline | Pulmonary Disease, Chronic Obstructive | 05/08 | 05/08 | | |
NCT01449799: An Investigation of the Pharmacokinetics of GSK961081 and Fluticasone Propionate in Healthy Volunteers |
|
|
| Completed | 1 | 24 | Europe | GSK961081 800 microgram dose, Fluticasone Propionate 500 microgram dose, GSK961081 800 microgram and Fluticasone Propionate 500 microgram separately, GSK961081 800 microgram Fluticasone Propionate 500 microgram in a blend | GlaxoSmithKline | Pulmonary Disease, Chronic Obstructive | 09/11 | 09/11 | | |
NCT02064504 / 2009-013801-33: Study to Determine the Pharmacokinetics of GSK961081 and Fluticasone Furoate When Administered Alone or in Combination |
|
|
| Completed | 1 | 48 | RoW | GSK961081, Fluticasone furoate | GlaxoSmithKline | Pulmonary Disease, Chronic Obstructive | 05/14 | 05/14 | | |
NCT02663089: A Phase 1 (Ph1), Single Dose (SD), GSK961081 Absorption, Distribution, Metabolism, and Excretion (ADME) Study in Healthy Subjects |
|
|
| Completed | 1 | 6 | Europe | [14C]-GSK961081 solution for IV infusion, [14C]-GSK961081 oral solution, GSK961081 dry powder for inhalation | Theravance Biopharma, Hammersmith Medicines Research, GlaxoSmithKline | Pulmonary Disease, Chronic Obstructive | 03/16 | 03/16 | | |
NCT02666287: GSK961081 Alone and With Fluticasone Furoate (FF), Phase 1 (Ph1), Single Dose Regimen (SD), Repeat Dose Regimen (RD), Pharmacokinetic (PK) Study in Healthy Volunteer (HV) |
|
|
| Completed | 1 | 48 | Europe | BAT/FF, BAT, FF, FF (MgSt), FF/Vilanterol | GlaxoSmithKline, Hammersmith Medicines Research | Pulmonary Disease, Chronic Obstructive | 06/16 | 06/16 | | |
